Clinical Scorecard: Immunogenicity of Anti-TNF Therapies in a Cohort of Patients with Inflammatory Bowel Disease from the Middle East: Frequency, Influencing Factors, and Contextual Drug Level Thresholds
At a Glance
Category
Detail
Condition
Inflammatory Bowel Disease (IBD)
Key Mechanisms
Immunogenicity of anti-TNF therapies leading to the development of anti-drug antibodies (ADA)
Target Population
Patients with inflammatory bowel disease in the Middle East
Care Setting
Tertiary care IBD facility in Abu Dhabi, United Arab Emirates
Key Highlights
Immunogenicity developed in 28.3% of anti-TNF treatment courses.
Infliximab and adalimumab had comparable immunogenicity rates.
Pre-event trough levels were significantly lower in immunogenic courses.
Subcutaneous infliximab showed lower immunogenicity than intravenous infliximab.
Prior surgery was identified as the strongest predictor of immunogenicity.
Guideline-Based Recommendations
Diagnosis
Immunogenicity defined by detectable anti-drug antibodies using a drug-tolerant electrochemiluminescent bridging immunoassay.
Management
Proactive therapeutic drug monitoring (TDM) is recommended to mitigate anti-TNF immunogenicity.
Monitoring & Follow-up
Regular monitoring of drug levels and anti-drug antibodies is essential for treatment optimization.
Risks
Immunogenicity-mediated failure is a leading cause of treatment discontinuation.
Patient & Prescribing Data
Adults (≥18 years) with confirmed IBD receiving anti-TNF therapy.
Adequate drug exposure through TDM-guided optimization may be more important than immunomodulator coprescription.
Clinical Best Practices
Consider subcutaneous infliximab for potentially lower immunogenicity.
Utilize drug level thresholds of 5.3 mcg/mL for infliximab and 6.4 mcg/mL for adalimumab to predict immunogenicity.
